We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 72,162 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/4/2024 10:43 | I would hope so with the wider exposure to the market this collaboration brings! | jusjusjus | |
25/4/2024 10:34 | Is this collaboration going to help funding? | pwal | |
25/4/2024 07:57 | Turned out to be coming days! | jusjusjus | |
23/4/2024 11:53 | You are right: In the coming weeks as stated later in the report. That would be great news. | pwal | |
23/4/2024 10:16 | Did they say in the coming weeks or in the near future? | pwal | |
23/4/2024 07:31 | Collaborations The Company is at advanced stages of finalising a collaboration with an independent global leader in R&D based in the US which, on the back of successful initial studies utilising our combined technologies, would lead to a co-marketing agreement to allow both parties to promote the resultant combined technology. We anticipate being able to make a further announcement on this in the coming weeks. | jusjusjus | |
23/4/2024 07:05 | Under GBP1m in cash and still no sign of ever generating any revenue.. I wonder how that will end up | dplewis1 | |
18/4/2024 07:09 | 18 April 2024 N4 Pharma plc ("N4 Pharma" or the "Company") Oral Delivery Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its ongoing oral delivery research work. The Company, through its research program with the University of Queensland, has undertaken further testing, in vivo, to show the successful delivery of a Nuvec® capsule into the intestine where it has released its plasmid DNA payload to produce localised protein expression. This work further demonstrates the potential of Nuvec® as an oral delivery system for multiple nucleotide payloads. Specifically, in this experiment an enterically coated capsule containing PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. Protein expression was significantly higher than control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In addition, a significantly higher ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec® sample compared to control. Nigel Theobald, Chief Executive Officer of the Company, commented: "This work once more clearly shows that Nuvec® has the potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential applications such as a vaccination with plasmid DNA or to deliver a local product for Irritable Bowel Disease or to treat colonic cancer among many possible examples. "We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application and further news on this will be announced when a program is identified. In the meantime, the University of Queensland will continue its work as part of our ARC funded grant with them." For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Engage with us directly at N4 Pharma Investor Hub | jakleeds | |
15/4/2024 11:18 | Report due soon? | pwal | |
15/4/2024 09:34 | Money moved to APH | blackhorse23 | |
01/3/2024 20:46 | Just like its abandoned sildenafil formulation . There is only one consistent constant with all these AIM so called pharma companies. And unfortunately nearly always involves shareholders funds ‘plumbing new depths’ | mdi | |
01/3/2024 15:05 | Plumbing new depths | dplewis1 | |
01/3/2024 13:57 | Posting the same article twice .. the exciting world of N4 | dplewis1 | |
01/3/2024 13:01 | Same article, different outlet. | fydo | |
29/2/2024 09:12 | Yes that’s why he has been posting so much; he is trying to ramp the price now he has upped his holding! | nobbygnome | |
29/2/2024 07:08 | It was enough to convince Farriar Fydo to buy some more anyway | dplewis1 | |
28/2/2024 20:47 | I wonder how much they paid the journal to publish that article….. | nobbygnome | |
28/2/2024 11:31 | I think we need another one of Nigel’s vacuous ‘positive̵ | nobbygnome | |
23/2/2024 22:07 | Well there are three of his sock puppets in quick succession. Yes I know, it’s pathetic but just filter them all like I do! | nobbygnome | |
23/2/2024 21:57 | Very true. They tend to come across as actually educated rather than needing to be educated | vlad the impaler | |
23/2/2024 21:52 | Has Nobby nothing venomously constructive to add? I've never heard a PhD person speak like a gerbil that got in the way of a lawnmower , before | institutional investments | |
23/2/2024 20:59 | As I say I can only apologise for the unwelcome appearance of the BBM Sheedy with his multiple sock puppets. Just filter them all. It’s really hard to understand why he spends hours logging in and out of his multiple accounts when we all know it’s the same sad person. | nobbygnome | |
23/2/2024 19:11 | But the real question. is, Nobbygnome, should we all believe you ? Would you be as naive as us? | institutional investments |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions